{"artifact":{"id":"rsc-h-76888762-b961b0ac","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: Perforant Path Presynaptic Terminal Protection Strategy","quality_score":0.3,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"h-76888762\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex as a biological variable, sex-disaggregated analysis, or sex-specific considerations","location":"Entire document"},"blinding":{"score":1,"evidence":"No mention of blinding procedures, investigator blinding, or outcome assessment blinding","location":"Entire document"},"study_design":{"score":2,"evidence":"stereotactic injection of AAV-PPARGC1A specifically into the entorhinal cortex at 1 month of age resulted in a 65-70% preservation","location":"Preclinical Evidence, paragraph 2"},"power_analysis":{"score":1,"evidence":"No mention of power calculations, sample size justification, or statistical power","location":"Entire document"},"data_availability":{"score":1,"evidence":"No mention of data sharing, code repositories, or public data access","location":"Entire document"},"scientific_premise":{"score":3,"evidence":"The perforant path represents one of the most metabolically demanding neuronal projections in the central nervous system","location":"Molecular Mechanism and Rationale, paragraph 1"},"statistical_reporting":{"score":1,"evidence":"Presynaptic proteins synaptophysin and VAMP2 at levels 70-80% of wild-type controls, compared to 30-40% reduction in untreated animals","location":"Evidence for Disease Modification, paragraph 3"},"resource_identification":{"score":2,"evidence":"The therapeutic strategy employs adeno-associated virus serotype 9 (AAV9) vectors engineered with the neuron-specific synapsin-1 promoter","location":"Therapeutic Strategy and Delivery, paragraph 1"}},"overall_summary":"This text represents a therapeutic hypothesis with strong biological plausibility but severe methodological deficiencies. While it articulates a coherent molecular rationale and references relevant animal models, it lacks fundamental rigor elements: no blinding, power analysis, or statistical reporting; no data/code availability statements; and no consideration of sex as a biological variable. The presentation reads more as a speculative therapeutic proposal than peer-reviewed preclinical evidence.","weakest_dimension":"sabv","strongest_dimension":"scientific_premise"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex as a biological variable, sex-matched experimental groups, or disaggregated results by sex anywhere in the preclinical studies.","location":"Entire document - no SABV considerations"},"blinding":{"score":1,"evidence":"No mention of blinding procedures, blinding status of assessors, or randomization in any described experiment.","location":"Entire document - no blinding information provided"},"study_design":{"score":2,"evidence":"stereotactic injection of AAV-PPARGC1A specifically into the entorhinal cortex at 1 month of age resulted in a 65-70% preservation of perforant path synaptic density at 6 months, compared to vector controls","location":"Preclinical Evidence, 5xFAD model section"},"power_analysis":{"score":1,"evidence":"Specific sample sizes, power calculations, or statistical justification for animal numbers are entirely absent from the preclinical evidence descriptions.","location":"Preclinical Evidence section - no power analysis mentioned"},"data_availability":{"score":1,"evidence":"No mention of data deposition, code repositories, supplementary materials, or public access to raw data.","location":"Entire document - no data availability statement"},"scientific_premise":{"score":3,"evidence":"The hypothesis centers on PPARGC1A (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a master regulator of mitochondrial biogenesis and oxidative metabolism, as the key molecular target for preventing the characteristic \"dying back\" axonopathy observed in neurodegenerative diseases.","location":"Molecular Mechanism and Rationale, paragraph 1"},"statistical_reporting":{"score":1,"evidence":"65-70% preservation, 45-50% synaptic loss, 80% of baseline LTP magnitude versus 35% in controls - percentages reported without statistical tests, p-values, confidence intervals, or dispersion measures.","location":"Preclinical Evidence section"},"resource_identification":{"score":2,"evidence":"AAV9 vectors engineered with the neuron-specific synapsin-1 promoter, 5xFAD transgenic mice, rTg4510 tauopathy model","location":"Therapeutic Strategy and Delivery section; Preclinical Evidence section"}},"overall_summary":"This hypothesis presents a biologically plausible therapeutic strategy for perforant path protection but demonstrates severe methodological deficiencies across multiple reporting dimensions. While the scientific premise draws on established models (5xFAD, rTg4510) and known biology of PPARGC1A, the preclinical evidence lacks essential rigor elements including blinding, power analysis, statistical reporting with tests and error measures, resource identification with RRIDs, data/code availability, and sex consideration as a biological variable.","weakest_dimension":"blinding (equally weak: power_analysis, statistical_reporting, data_availability, sabv)","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"glm","reconciled":{"reconciler_notes":"Complete convergence between Evaluator A and B across all 8 dimensions. Both evaluators assigned identical scores (3,2,1,1,2,1,1,1) with substantial agreement in evidence identification and phrasing. The strongest dimension is scientific_premise (score 3) reflecting solid biological plausibility of the PPARGC1A therapeutic strategy. The weakest dimensions are blinding, power_analysis, statistical_reporting, data_availability, and sabv (all score 1), indicating severe methodological deficiencies in reporting rigor. No formal Cohen's kappa calculation possible with only 2 raters and 8 observations. Notable: evaluators independently identified the same critical gap - quantitative results are reported as percentages without statistical tests, p-values, confidence intervals, or dispersion measures.","overall_agreement":"high","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of sex as a biological variable, sex-disaggregated analysis, or sex-specific considerations","b_evidence":"No mention of sex as a biological variable, sex-matched experimental groups, or disaggregated results by sex anywhere in the preclinical studies.","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of blinding procedures, investigator blinding, or outcome assessment blinding","b_evidence":"No mention of blinding procedures, blinding status of assessors, or randomization in any described experiment.","disagreement":false},"study_design":{"score":2,"a_score":2,"b_score":2,"a_evidence":"stereotactic injection of AAV-PPARGC1A specifically into the entorhinal cortex at 1 month of age resulted in a 65-70% preservation","b_evidence":"stereotactic injection of AAV-PPARGC1A specifically into the entorhinal cortex at 1 month of age resulted in a 65-70% preservation of perforant path synaptic density at 6 months, compared to vector controls","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of power calculations, sample size justification, or statistical power","b_evidence":"Specific sample sizes, power calculations, or statistical justification for animal numbers are entirely absent from the preclinical evidence descriptions.","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of data sharing, code repositories, or public data access","b_evidence":"No mention of data deposition, code repositories, supplementary materials, or public access to raw data.","disagreement":false},"scientific_premise":{"score":3,"a_score":3,"b_score":3,"a_evidence":"The perforant path represents one of the most metabolically demanding neuronal projections in the central nervous system","b_evidence":"The hypothesis centers on PPARGC1A (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a master regulator of mitochondrial biogenesis and oxidative metabolism, as the key molecular target for preventing the characteristic \"dying back\" axonopathy observed in neurodegenerative diseases.","disagreement":false},"statistical_reporting":{"score":1,"a_score":1,"b_score":1,"a_evidence":"Presynaptic proteins synaptophysin and VAMP2 at levels 70-80% of wild-type controls, compared to 30-40% reduction in untreated animals","b_evidence":"65-70% preservation, 45-50% synaptic loss, 80% of baseline LTP magnitude versus 35% in controls - percentages reported without statistical tests, p-values, confidence intervals, or dispersion measures.","disagreement":false},"resource_identification":{"score":2,"a_score":2,"b_score":2,"a_evidence":"The therapeutic strategy employs adeno-associated virus serotype 9 (AAV9) vectors engineered with the neuron-specific synapsin-1 promoter","b_evidence":"AAV9 vectors engineered with the neuron-specific synapsin-1 promoter, 5xFAD transgenic mice, rTg4510 tauopathy model","disagreement":false}},"inter_rater_agreement":"N/A","dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"h-76888762","scored_entity_type":"hypothesis","scored_entity_title":"Perforant Path Presynaptic Terminal Protection Strategy"},"created_at":"2026-04-19T03:22:16.502962-07:00","updated_at":"2026-04-19T03:22:16.502970-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-19T03:22:16.502962-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":"ok","contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"ae2c29d0-d04e-4e3d-b000-c87a26555f65","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"analysis-sda-2026-04-01-gap-004","link_type":"derives_from","strength":1.0,"evidence":"rigor_score_card.scored_entity=h-76888762 -> hypotheses.analysis_id=sda-2026-04-01-gap-004"}],"incoming_links":[],"current_artifact_id":"rsc-h-76888762-b961b0ac","is_canonical":true,"supersede_chain":["rsc-h-76888762-b961b0ac"]}